Compare BridgeBio Pharma Inc (BBIO) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Stanley Black & Decker, Inc. — how do they compare? BridgeBio Pharma Inc trades at $84.58 (market cap $16.36B), while Stanley Black & Decker, Inc. trades at $102.68 (market cap $15.71B). The key difference: BridgeBio Pharma Inc and Stanley Black & Decker, Inc. are close in size by market cap, and Stanley Black & Decker, Inc. pays a 3.23% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | SWK | |
|---|---|---|
Market Cap | $16.36B | $15.71B |
Sector | Health | — |
52-Week High | $90.17 | $104.00 |
52-Week Low | $47.29 | $62.12 |
Enterprise Value | $18.14B | $19.87B |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.57, down slightly by 0.12% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth driven by Attruby sales, though it missed EPS estimates. With a high P/S ratio of 22.77 and negative profitability metrics, the stock is priced for future growth, supported by strong analyst buy ratings and a $104.56 consensus price target.
The outlook hinges on successful product launches and regulatory approvals, with three potential launches expected within 12 months offering significant upside. Key risks include persistent cash burn, high debt, and execution challenges in bringing new treatments to market, which could pressure the stock if milestones are missed.
SWK trades at $102.9, up 0.25% today, with a bullish technical signal from moving averages but overbought RSI levels near 80. The company reported strong Q2 2026 earnings, beating EPS estimates with $1.57 versus $1.21 expected, and raised full-year guidance. Revenue for 2025 was $15.13B, with net income margin improving to 2.65%. Recent news highlights a $1 billion U.S. investment plan and institutional buying, supporting positive momentum.
The outlook is cautiously optimistic, with earnings growth and margin expansion driving potential upside, though the stock trades above the consensus price target of $93.67. Risks include debt levels and economic sensitivity, but institutional accumulation and dividend stability offer support. The current price near resistance at $105 may limit near-term gains despite fundamental improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
